Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.51 |
| ▸ | HTR1A | P08908 | 5/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | HTR2A | P28223 | 4/20 | 0.49 |
| ▸ | HTR7 | P34969 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097421 | 0.97 | HTR6 (0.52) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL5097214 | 0.90 | HTR6 (0.65) | HTR6HTR1ADRD2CYP3A4 | |
| SCHEMBL5097484 | 0.87 | HTR6 (0.61) | HTR6HTR1ADRD2CYP3A4 | |
| SCHEMBL3670406 | 0.85 | HTR6 (0.61) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL14100662 | 0.85 | HTR6 (0.43) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL13993619 | 0.85 | HTR6 (0.61) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL3670408 | 0.85 | HTR6 (0.61) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL5097560 | 0.84 | HTR6 (0.69) | HTR6HTR1ADRD2 | |
| SCHEMBL5097194 | 0.84 | HTR6 (0.49) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL5097185 | 0.84 | HTR6 (0.49) | HTR6HTR1ADRD2HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | claimed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008101247-A2 | 6 ' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1B, HTR1A | HTR6 1/4885HTR1A 3/4885DRD2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.